FILE:PFE/PFE-8K-20050624095020.txt.gz
EVENTS:	Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
TEXT:
ITEM: Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions:
[ ] Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
Under the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the authorized undersigned.
 

NEW YORK, June 24 - Pfizer Inc said today that Jean-Paul Valls, Ph.D., a member of the companys Board of Directors, has resigned from the Board.
Valls is Chairman Emeritus and Director of Minerals Technologies Inc., a resource-and-technology-based mineral products company. He joined Pfizers Board of Directors in 1980 and is a former Vice Chairman of Pfizer. He resigned for personal reasons.
Jean-Paul Valls has made many important contributions to Pfizer and our Board during his long service, said Hank McKinnell, Pfizer chairman and chief executive officer. We greatly value the insight and experience he has brought to our company during an era of significant growth and success for Pfizer.
 


